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We have previously demonstrated that long-term exposure of bovine tracheal smooth 
muscle (BTSM) strips to insulin induces a functional hypercontractile phenotype. To 
elucidate molecular mechanisms by which insulin might induce maturation of contractile 
phenotype airway smooth muscle (ASM) cells, we investigated effects of insulin 
stimulation in serum-free primary BTSM cell cultures on protein accumulation of 
specific contractile phenotypic markers, and on the abundance and stability of mRNA 
encoding these markers. In addition, we used microscopy to assess insulin effects on 
ASM cell morphology, phenotype, and induction of PI-3-kinase signaling. It was 
demonstrated that protein and mRNA levels of smooth muscle specific contractile 
phenotypic markers, including sm-myosin, are significantly increased after stimulation 
of cultured BTSM cells with insulin (1 µM) for 8 days as compared to cells treated with 
serum-free media, while mRNA stability was unaffected. In addition, insulin-treatment 
promoted the formation of large, elongate ASM cells, characterized by dramatic 
accumulation of contractile phenotype marker proteins and phosphorylated p70S6K 
(downstream target of PI-3-kinase associated with ASM maturation). Insulin effects on 
protein accumulation and cell morphology were abrogated by combined pretreatment 
with the Rho-kinase inhibitor Y-27632 (1 µM) or the PI-3-kinase inhibitor LY-294002 
(10 µM), indicating that insulin increases the expression of contractile phenotypic 
markers in BTSM in a Rho-kinase and PI-3-kinase dependent fashion. In conclusion, 
insulin increases transcription and protein expression of contractile phenotypic markers 
in ASM. This could have important implications for the use of recently approved 





Chronically inflamed airways are subject to airway remodeling, which may contribute 
importantly to airway hyperresponsiveness (AHR) and progressive decline of lung 
function in chronic and severe asthma [1-3]. It is well recognized that mature airway 
smooth muscle (ASM) cells retain the ability for phenotype plasticity, enabling them to 
exert contractile, proliferative, migratory and synthetic functional responses that likely 
contribute to asthma pathogenesis [4,5]. Modulation of ASM phenotype is governed by 
growth factors, neurotransmitters and inflammatory mediators. In vitro, ASM cells and 
intact tissue strips switch to a less contractile, more proliferative phenotype when 
exposed to high concentrations of fetal bovine serum (FBS) or peptide growth factors 
[4,6]. Such a phenotype shift is accompanied by a decrease in contractile ability that 
occurs concomitantly with a dramatic decrease in expression of specific contractile 
proteins, such as smooth muscle myosin heavy chain (sm-MHC) [4]. On the other hand, 
induction of a (hyper)contractile phenotype in cultured myocytes occurs as a 
consequence of growth arrest by serum-deprivation, a process characterized by enhanced 




expression of contractile proteins and contraction regulatory proteins, such as calponin 
and myosin light chain kinase (MLCK) [4,7]. 
 
In airways from asthmatic patients, excessive accumulation of contractile ASM has 
frequently been described [8], and likely results from both myocyte hyperplasia and 
hypertrophy in central and small airways [9-11]. ASM thickening is considered to be the 
pivotal component of airway remodeling that underpins excessive airway narrowing in 
asthma [12]. Prolonged serum-deprivation of ASM cells has been used successfully to 
study processes involved in the development of large, elongate contractile ASM cells. 
Maturation of ASM cells was accompanied by an increase in protein expression of 
specific contractile phenotypic markers such as sm-MHC [4,7] that occurred in the 
absence of any change in sm-MHC mRNA abundance [13], while transcriptional activity 
was reduced [14]. Myocyte elongation and sm-MHC protein accumulation is dependent 
on protein translational regulation by a pathway involving phosphatidylinositol-3-kinase 
(PI-3-kinase), mammalian Target of Rapamycin (mTOR) and p70S6K [13]. 
Transcription of genes encoding specific contractile proteins appears to mediated 
primarily by the Rho/Rho-kinase pathway [3,15,16]. This signaling pathway promotes 
nuclear translocation of the transcription factor serum response factor (SRF), which 
binds CArG box elements to activate promoter function [14,17,18]. Notably, studies 
describing the effects of prolonged serum-deprivation on ASM phenotype and function 
have been performed in the absence of serum, but also in the presence of insulin, which 
was added to serve as a survival/attachment promoting factor. To date, however, it has 
not been determined to what extent insulin may contribute directly to ASM maturation 
via the signaling pathways that are known to be critical in this process. 
 
Long-term exposure (8 days) of bovine tracheal smooth muscle (BTSM) strips to insulin 
has been shown to induce a functional hypercontractile ASM phenotype characterized by 
increased contractile response to methacholine and KCl, and decreased proliferative 
response to growth factor [19]. Beyond its biological importance, the effects of insulin 
on ASM function are of clinical relevance, as the use of aerosolized insulin formulations 
has recently been approved in Europe and the U.S.A. for the treatment of diabetes 
mellitus type 1 and 2 [20].  
 
To elucidate molecular mechanisms by which insulin might underpin maturation of 
contractile phenotype ASM cells, we investigated the effects of insulin stimulation in 
serum-free primary cultures on protein accumulation of specific contractile phenotypic 
markers, and on the abundance and -stability of mRNA encoding contractile phenotype 
markers. In addition, we used microscopy to assess insulin effects on ASM cell 
morphology, phenotype, and induction of PI-3-kinase signaling. As Rho-kinase [3,15] 
and PI-3-kinase [13] are tightly associated with transcription and translation of 
contractile phenotypic markers, respectively, we also studied the effects of the selective 
Rho-kinase inhibitor Y-27632 and the selective PI-3-kinase inhibitor LY-294002 on 








Airway smooth muscle cell and organ culture 
Bovine tracheae were obtained from local slaughterhouses and rapidly transported to the 
laboratory in Krebs-Henseleit (KH) buffer of the following composition (mM): NaCl 
117.5, KCl 5.60, MgSO4 1.18, CaCl2 2.50, NaH2PO4 1.28, NaHCO3 25.00 and glucose 
5.50, pregassed with 5% CO2 and 95% O2; pH 7.4. After the removal of mucosa and 
connective tissue, tracheal smooth muscle was chopped using a McIlwain tissue chopper, 
three times at a setting of 500 M and three times at a setting of 100 M. Tissue particles 
were washed two times with sterile Dulbecco’s modification of Eagle’s medium 
(DMEM) supplemented with NaHCO3 (10 mM), HEPES (20 mM), sodium pyruvate (1 
mM), nonessential amino acid mixture (1:100), gentamicin (45 g/ml), penicillin (100 
U/ml), streptomycin (100 g/ml), amphotericin B (1.5 g/ml) and 0.5 % fetal bovine 
serum (FBS). Enzymatic digestion was performed in the same medium, supplemented 
with collagenase P (0.75 mg/ml), papain (1 mg/ml) and soybean trypsin inhibitor (1 
mg/ml). During digestion, the suspension was incubated in an incubator shaker at 37 ˚C, 
55 rpm for 20 min, followed by a 10 min period of shaking at 70 rpm. After filtration of 
the obtained suspension over 50 m gauze, bovine tracheal smooth muscle (BTSM) cells 
were washed three times in medium supplemented with 10% FBS (S+). Cells were 
grown to 70-80 % confluence (time-point 0) in 6-well plates, after which they were kept 
in DMEM (S0) or DMEM supplemented with insulin (1 M) in the presence or absence 
of (+)-(R)-trans-4-(1-aminoethyl)-N-(4-pyridyl) cyclohexane carboxamide (Y-27632, 
1M) and/or 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one (LY-294002, 10 M) 
for 2, 4 or 8 days. Each condition was performed in triplicate for each experiment. For 
all protocols, cells in passage 1-3 were used. In separate experiments, organ culture of 
BTSM strips under serum-deprived or insulin-stimulated conditions was performed as 
described previously [19]. 
 
Western analysis 
To obtain whole cell lysates, cells were washed once with ice-cold phosphate-buffered 
saline (PBS, composition (mM): NaCl 140.0; KCl 2.6; KH2PO4 1.4; Na2HPO4.2H2O 8.1; 
pH 7.4) and then lysed in ice-cold RIPA buffer (composition: 40 mM Tris, 150 mM 
NaCl, 1 % Igepal, 1 % deoxycholic acid, 1 mM NaF, 1 mM Na3VO4, 10 µg/ml aprotinin, 
10 µg/ml leupeptin, 7 µg/ml pepstatin A, 1 mM PMSF, pH 8.0). Equal amounts of 
protein were subjected to electrophoresis and transferred to nitrocellulose or 
polyvinylidene difluoride membranes. Membranes were subsequently blocked in 
blocking buffer (composition: Tris-HCl 50.0 mM; NaCl 150.0 mM; Tween-20 0.1%, 
dried milk powder 5%) for 90 minutes at room temperature. Next, membranes were 
incubated overnight at 4 °C with primary antibodies (sm-myosin (diluted 1:200), 
calponin (diluted 1:400) and -actin (diluted 1:2000); all dilutions in blocking buffer). 
After three washes with Tris Buffered Saline Tween 20 (0.1 % TBST, containing Tris-
HCl 50.0 mM; NaCl 150.0 mM, Tween 20 0.1 %) of 10 min each, membranes were 
incubated with horseradish peroxidase-labelled secondary antibodies (dilution 1:3000 in 
blocking buffer) at room temperature for 90 min, followed by an additional three washes 




with 0.1 % TBST. Bands were subsequently visualized on film using enhanced 
chemiluminescence reagents (Amersham, Buckinghamshire, UK) and analyzed by 
densitometry (TotallabTM). All bands were normalized to -actin expression.  
 
RNA extraction and reverse transcriptase PCR 
Total RNA was extracted using a RNeasy RNA Mini Kit (Qiagen, U.S.A) in accordance 
with the manufacturer’s instructions. Reverse transcription (first strand cDNA synthesis) 
was performed with 2 g of total RNA (in x l), 1 l Oligo dT12-18 primer (500 mg/ml, 
Invitrogen) and 10-x l ddH2O. After heating this mixture for 5 min at 65 °C, 9 l of 
reaction mixture, consisting of 1 l dNTP PCR mix (10 mM, Amersham, Canada), 4 l 
5x first-strand buffer, 2 l DTT (0.1 M), 1 l RNaseOUT (40 U) and 1 l Moloney 
murine leukemia virus reverse transcriptase (M-MLV RT, 200 U, Invitrogen) was added. 
Subsequently, the samples were incubated at 42 °C for 120 minutes, after which the 
reaction was inactivated by heating the samples at 72 °C for 15 minutes and putting them 
on ice. cDNA was stored at -20 °C until further use. 
PCR amplification was performed in a total volume of 50 l which included 1 l RT 
reaction mixture, 0.5 M of each forward and reverse oligonucleotide, 1x PCR buffer 
with 1.5 mM MgCl, 0.2 mM dNTP PCR mix and 1.25 U of Platinum Taq Polymerase 
(Invitrogen). The following primers were used: to amplify a 162-bp fragment of Bos 
Taurus (bovine) insulin receptor cDNA; 5’-AAA CGG ACG GAT TCT GAC TTT-3’ 
(forward) and 5’-GTG ATC TCT GAG CTC CGT TTG -3’ (reverse); to amplify a 150-
bp fragment of bovine Insulin-Like Growth Factor Receptor (IGFR)-1 cDNA; 5’-CCG 
GGA GGT CTC CTC TAC TA-3’ (forward) and 5’-TTG TGT CCT GAG TGT CTG 
TCG-3’ (reverse); and, to amplify a 247-bp fragment of bovine IGFR-2 cDNA; 5’-CGT 
GTT TGA TCT GAA CCC ACT-3’ (forward) and 5’-CCC CGT GTA GTT CAG GGT 
TAT-3’ (reverse). PCR comprised of a denaturing step of 94°C for 5 minutes followed 
by amplification of 10 cycles at 94°C for 1 minute, 67°C for 1 minute decreasing 1°C 
per cycle, and 72°C for 1 minute, and then 20 cycles of 94°C for 1 minute, 57°C for 1 
minute, and 72°C for 1 minutes, with a final extention at 72°C for 5 minutes. PCR 
products were separated on a 2% agarose gel.  
 
Real Time PCR 
cDNA was subjected to real time PCR, which was performed with a LightCycler (Roche 
Molecular Biochemicals) and LightCycler FastStart DNA Master SYBR Green I 
(SYBR-GR, Roche Molecular Biochemicals) in accordance with the manufacturer’s 
instructions. The following primer sets were used: to amplify a 158-bp fragment of 
bovine sm-MHC-I cDNA; 5’-ATG TTC CAG TCC ACA ATA GGA GA-3’ (forward) 
and 5’-TGT GTC AAT GGC AGA ATC AAT AG-3’ (reverse); and, to amplify a 136-
bp fragment of G3PDH cDNA; 5’-AGC AAT GCC TCC TGC ACC ACC AAC-3’ 
(forward) and 5’-CCG-GAG GGG CCA TCC ACA GTC T (reverse). Changes in sm-






Analysis of mRNA stability 
Cells were grown to 70-80 % confluence then were kept in S0 or medium containing 
insulin (1 M) for 0, 6 or 24 hr in the presence of actinomycin D (1 g/ml) to inhibit de 
novo RNA-synthesis. Total RNA was extracted and real time PCR was used to assess 
sm-MHC-I expression at each time point. G3PDH mRNA abundance, which was 
unaltered by actinomycin D over the time course of our experiments, was used to 
normalize sm-MHC-1 transcript abundance.  
 
Phase-contrast microscopy and immunocytochemistry 
For all imaging experiments, before plating cells in 6-well plates, a pre-cleaned, sterile 
glass coverslip was placed in each well. BTSM cells were grown to 70-80% confluence 
as described above, then were maintained in S0 or S0 supplemented with insulin (1M) 
in the absence or presence of Y-27632 (1 M) and/or LY-294002 (10 M) for 2, 4 or 8 
days. 
Coverslips were removed from each well to obtain phase contrast images using an 
Olympus AX70 microscope equipped with digital image capture system (ColorView 
Soft system with Olympus U CMAD2 lens). Using AnalySIS® image processing 
software, a scale bar representing 100 m was added to each picture. Quantitative 
analysis of cell number and length was performed using Image Pro Plus® software. 
Immunocytochemistry was performed as we have previously described [13]. Briefly, 
cells were maintained in S0 or S0 supplemented with insulin (1M ) for 8 days, were 
fixed with 4% paraformaldehyde and permeabilized using 0.1% Triton-X 100. 
Thereafter cells were incubated in blocking solution containing 10% normal donkey 
serum, and then stored overnight at 4°C in diluted primary antibody solutions that 
included monoclonal mouse anti-sm-MHC (clone hSMv, Sigma-Aldrich, St. Louis, MO), 
monoclonal mouse anti-calponin (clone hCP, Sigma-Aldrich, St.Louis, MO), and rabbit-
anti-phosphorylated p70S6K(Thr421/Ser424) (Cell Signaling Tech., Beverly, MA). FITC- 
and Cy5-conjugated secondary antibodies (Jackson ImmunoResearch, West Grove, PA) 
were used to detect primary antibody bound to cells. Nuclei were labeled with Hoechst 
33342 (10 µg/mL). Coverslips were mounted using ProLong Anti-fade Gold (Invitrogen 
Canada, Burlington, ON) and images were captured using an Olympus LX70 inverted 
microscope equipped with a high resolution Ultra Pix FSI CCD camera controlled by 
Ultraview 4.0 Software (Olympus Canada, Markham, ON). 
 
Data analysis 
All data represent means ± s.e.mean from n separate experiments. Statistical significance 
of differences was evaluated by the Student's t-test for paired observations or the 
multiple measurement ANOVA, where appropriate. Differences were considered to be 
statistically significant when P<0.05. 
 
Materials 
Dulbecco’s modification of Eagle’s medium (DMEM), fetal bovine serum, bovine serum 
albumin, sodium pyruvate solution (100 mM), non-essential amino acid mixture, 
gentamicin solution (10 mg/ml), penicillin/streptomycin solution (5000 U/ml; 5000 




g/ml) and amphotericin B solution (Fungizone, 250 g/ml) were obtained from Gibco 
BRL Life Technologies (Paisley, UK). Mouse monoclonal anti--actin, mouse 
monoclonal anti-sm--actin, human apo-transferrin, soybean trypsin inhibitor and insulin 
(from bovine pancreas) were obtained from Sigma Chemical Co. (St. Louis, MO, USA). 
Mouse monoclonal anti-sm-myosin and mouse monoclonal anti-calponin were from 
Neomarkers (Fremont, CA, USA). Primary and secondary antibodies used for 
immunocytochemistry included monoclonal mouse anti-sm-MHC (clone hSMv, Sigma-
Aldrich, St. Louis, MO), monoclonal mouse anti-calponin (clone hCP, Sigma-Aldrich, 
St.Louis, MO), and rabbit-anti-phosphorylated p70S6K(Thr421/Ser424) (Cell Signaling 
Tech., Beverly, MA). FITC- and Cy5-conjugated secondary antibodies were obtained 
from Jackson ImmunoResearch, West Grove, PA. Collagenase P and papain were from 
Boehringer (Mannheim, Germany). L(+)ascorbic acid was from Merck (Darmstadt, 





Time-dependent effects of insulin on accumulation of contractile proteins 
The abundance of the contractile proteins sm-myosin and calponin was determined by 
Western analysis (Figure 1). To ensure that we were able to effectively study effects of 
insulin on ASM cell differentiation, the experiments were initiated using subconfluent 
cultures, as at 100% confluence, likely due to density-dependent mechanisms, ASM cells 
can start to differentiate spontaneously even in the presence of serum [4]. 
BTSM cells were grown to 70-80 % confluence in the presence of serum (S+)(day 0), 
after which they were maintained in serum-free conditions to enable assessment of the 
direct and exclusive effects of insulin exposure for up to 8 days. Insulin exposure 
induced a significant and continual accumulation of both sm-myosin (Figure 1A, D) and 
calponin (Figure 1B, D) over the 8 days of study. Indeed, protein abundance was 
increased by ~9-fold and ~4-fold for sm-myosin and calponin, respectively, compared to 
day 0. In contrast, in the absence of insulin contractile protein abundance increased by 
only ~1- (sm-myosin) and ~2-fold (calponin); which was not statistically significant for 
sm-myosin (P=0.2 for sm-myosin). Overall, 8 days after serum withdrawal insulin 
exposure induced at least 5-times more sm-myosin and 2-times more calponin than was 
observed for myocytes maintained in serum-free culture without added insulin. 
Importantly, no difference was detected in myocyte attachment or viability in serum-
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Figure 1. Insulin induces contractile protein accumulation in BTSM cells in a time-dependent 
fashion. Western analysis was performed using whole cell lysates prepared from prolonged insulin 
stimulated (1 µM, closed symbols) or serum-deprived (S0, open symbols) BTSM cell cultures. (A) 
Comparison by densitometry showed that insulin significantly increases sm-myosin protein 
expression as compared to expression on day 0 and expression after 8 d. of serum-deprivation. No 
significant increase was observed under serum-deprived conditions. (B) Comparison by 
densitometry showed that insulin significantly augments calponin protein expression as compared 
to expression on day 0 and expression after 8 d. of serum-deprivation. In addition, calponin 
expression was also enhanced under serum-deprived conditions as compared to day 0. (C) As 
compared to expression levels in 8 d. serum-deprived BTSM strips, expression of sm-myosin, 
determined by densitometric analysis, is significantly augmented in homogenates prepared from 8 
d. insulin-stimulated BTSM strips. (D) Representative Western blots for sm-myosin (upper panel), 
calponin (middle panel) and -actin (lower panel) in whole cell lysates from BTSM cell cultures 
kept under insulin-stimulated or serum-deprived conditions for 0-8 d. For each experiment 
expression levels were normalized to that on day 8 under insulin stimulated conditions. Data 
shown represent means ± s.e.mean of 4 (A), 8 (B) and 3 (C) independent experiments. *P<0.05, 
**P<0.01, ***P<0.001 compared to 8 d. S0; #P<0.05, # #P<0.01 compared to day 0. 
 
To be sure that the insulin effects were not an artifact of using primary cultured 
myocytes, we also measured the effects of 8 day insulin exposure on sm-myosin 
abundance in organ cultured BTSM strips (Figure 1C). As observed for the primary 




cultured myocytes, prolonged insulin stimulation resulted in a significantly greater 
abundance of sm-myosin compared to BTSM strips cultured in serum-free media 
without insulin. This strongly suggests that insulin effects on contractile protein 
abundance are consistent between cultured cells and intact BTSM. Furthermore, the 
results with organ culture are fully in line with the previously demonstrated development 
of hypercontractile responses in BTSM strips exposed to insulin in prolonged organ 
culture [19]. 
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Figure 2. Insulin increases sm-MHC mRNA content, without affecting its stability, in BTSM cells 
in a time dependent fashion. Real time PCR was performed using total RNA extracted from whole 
cell lysates prepared from prolonged insulin stimulated (1 µM, closed symbols) or serum-deprived 
(S0, open symbols) BTSM cell cultures. (A) Analysis shows that insulin significantly increases 
sm-MHC mRNA content in a time-dependent fashion, similar to that observed for protein 
accumulation. Serum deprivation tends to increase sm-MHC mRNA content as well, although no 
significant differences were observed. (B) In the presence of actinomycin D (1 µg/ml), which 
inhibits de novo RNA synthesis, no differences between insulin stimulated and serum-deprived 
conditions were observed for up to 24 hr. Thus, the effects of insulin on sm-MHC mRNA 
abundance (as compared to serum-deprivation) are not due to an increased mRNA stability. Data 
shown represent means ± s.e.mean of 3 independent experiments. *P<0.05, compared to 8 d. S0; 
#P<0.05 compared to day 0. 
 
Time-dependent effects of insulin on accumulation of contractile phenotype mRNA 
sm-MHC is considered to be one of the most stringent markers for mature contractile 
ASM cells [4]. Therefore, we determined the effects of insulin exposure of cultured 
BTSM cells on the abundance of mRNA for sm-MHC using real time PCR (Figure 2A). 
After 8 days, insulin stimulation had induced a significantly greater increase in sm-MHC 





MHC mRNA abundance in insulin exposed cultures was almost 3-fold greater than that 
measured on day 0, and mimicked the time-dependent accumulation of sm-myosin 
protein (Figure 1). Though there appeared to be a trend for accumulation of sm-MHC 
mRNA in insulin-deficient cultures, after 8 days exposure the abundance of this 
transcript was not significantly different from day 0 (P=0.2). 
In a separate set of experiments we determined the effects of serum-deprivation and 
insulin stimulation on sm-MHC mRNA stability. Actinomycin D (1 µg/ml), an inhibitor 
of de novo RNA synthesis, was added to BTSM cells at day 0, when subconfluent 
cultures were switched to serum-free culture media. Thereafter, we monitored sm-MHC 
mRNA abundance for up to 24 hours in the presence or absence of insulin. As shown in 
Figure 2B, no effects of insulin on the rate of sm-MHC mRNA degradation were 
observed in comparison with the serum-deprived control. This suggests that the 
potentiating effects of insulin on sm-MHC mRNA accumulation in prolonged serum-free 
culture may occur at the level of transcription. Of note, no effects of actinomycin D were 
observed on G3PDH mRNA expression, which was used to normalize real time PCR 
data obtained for sm-MHC. 
 
Intracellular signaling underlying insulin-induced contractile protein accumulation 
In ASM, Rho-kinase has emerged to be critically involved in transcription of genes 
encoding for contractile proteins [3,15], while at the level of protein translation, a critical 
role for PI-3-kinase signaling has been identified in ASM cell differentiation [13]. To 
study the involvement of Rho-kinase and PI-3-kinase in insulin-stimulated expression of 
contractile phenotype marker proteins, we co-incubated BTSM cells with insulin and 
selective inhibitors of Rho kinase (Y-27632, 1 µM) and PI-3-kinase (LY-294002, 10 µM) 
[21-23][Chapters 6 & 8] for 8 days (Figure 3). Inhibition of Rho-kinase or PI-3-kinase 
significantly reduced accumulation of both sm-myosin and calponin in the presence of 
insulin. In the case of calponin, complete blockade was evident so accumulation in the 
presence of each of the inhibitors was similar to that seen in serum-free cultures in the 
absence of insulin. These data may suggest that the excessive accumulation of sm-
myosin and calponin stimulated by insulin is dependent on both Rho-kinase and PI-3-
kinase signaling. Remarkably, in the presence of insulin we observed an additive effect 
of the Rho-kinase and PI-3-kinase inhibitors in which accumulation of sm-myosin and 
calponin was virtually abolished. This observation suggests Rho-kinase and PI-3-kinase 
signaling may act in parallel, potentially through different mechanisms, during ASM 
maturation in the presence of insulin. 
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Figure 3. Rho-kinase and PI-3-kinase are required for insulin-induced contractile protein 
accumulation. Western analysis was performed using whole cell lysates prepared from BTSM cell 
cultures that were maintained under insulin-stimulated (1 µM) or serum-deprived (S0) conditions 
in the absence or presence of Y-27632 (1 µM), LY-294002 (10 µM) or both for 8 d. (A) 
Comparison by densitometry showed that the increased sm-myosin protein expression in response 
to 8 d. insulin stimulation is strongly reduced after co-incubation with Y-27632 (1 µM) or LY-
294002 (10 µM) and is even further reduced by combined pretreatment. In addition, LY-294002, 
but not Y-27632, affected sm-myosin expression under serum-deprived conditions as well. (B) 
Densitometric analysis revealed that the insulin-induced increase in calponin is normalized by Y-
27632 (1 µM) or LY-294002 (10 µM) and is even further decreased by combined pretreatment 
with these inhibitors. As for sm-myosin, LY-294002, but not Y-27632, decreased calponin content 
under serum-deprived conditions. (C) Representative Western blots for sm-myosin (upper panel), 
calponin (middle panel) and -actin (lower panel) in whole cell lysates from BTSM cell cultures 
kept under insulin-stimulated (1 µM) or serum-deprived (S0) conditions in the absence or 
presence of Y-27632, LY-294002 or both for 8 d. For each experiment expression levels were 
normalized to that on day 8 under insulin stimulated conditions. Data shown represent means ± 
s.e.mean of 4 (A) and 5 (B) independent experiments. **P<0.01, ***P<0.001 compared to insulin; 





Notably, in contrast to our observation using insulin-stimulated cultures, no effect of 
Rho-kinase inhibition was observed on contractile protein expression in insulin-free 
conditions after 8 days. However, the effects of PI-3-kinase inhibition were similar to 
that observed in insulin-stimulated cultures (Figure 3). Moreover, no additive effects of 
combined treatment with Y-27632 and LY-294002 in insulin-deficient conditions were 
measured. Collectively, these observations suggest that serum-deprivation-induced 
increases in protein abundance are dependent on PI-3-kinase, but not Rho-kinase, while 
both PI-3-kinase and Rho-kinase appear to be necessary for insulin-augmented 
accumulation of sm-myosin and calponin. 
 
 
Figure 4. Maturation of a subset of BTSM cells into large, elongate contractile phenotype 
myocytes in insulin-supplemented cultures. Primary cultured BTSM cells on glass coverslips were 
grown in DMEM/10% FBS to 70%-80% confluence, then were maintained for 8 days in serum-
free DMEM supplemented with 1M insulin. Cells were fixed and labeled for calponin (green) or 
sm-MHC (red). Original images were captured using either a 10x objective (A & B) or 40x 
objective (C & D). Nuclei (blue) are stained with Hoechst 33342. Images are typical of those 








Effects of insulin on airway smooth muscle cell morphology and phenotype 
It has been previously established for canine ASM cells, that serum deprivation in the 
presence of insulin induces the maturation of a select subset of myocytes that are 
characteristically large and elongate and exhibit abundant accumulation of contractile 
proteins such as sm-MHC and calponin [7,24]. Thus, we assessed myocyte phenotype 
and morphology resulting from prolonged serum deprivation in the presence and absence 
of insulin. BTSM cells were grown to 70 % confluence on glass coverslips, after which 
they were serum-deprived or stimulated with insulin for up to 8 days. Consistent with 
previous reports, ~1/6 to 1/5 of BTSM cells exhibited dramatic accumulation of 
contractile phenotype marker proteins in insulin-supplemented, serum-free media 
(Figure 4). In the subconfluent state (70%), where both proliferating and 
nonproliferating cells were present, only low level labeling of sm-MHC and calponin 
that was without clear filamentous organization was evident ( not shown). 
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Figure 5. Inhibition of Rho-kinase or PI-3-kinase prevents the formation of large, elongate 
contractile ASM cells in insulin-stimulated BTSM cell cultures. Shown in this Figure are phase 
contrast micrographs of (A) some differentiated elongate BTSM cells after 8 days of serum-
deprivation and (B) bundles of differentiated elongate BTSM cells that develop after 8 days of 
insulin stimulation, a process which is prevented in the presence of Y-27632 (1 µM, C) or LY-
294002 (10 µM, D). Bar=100 µM. (E) Quantitative analysis using Image Pro Plus® software 
shows a time-dependent increase in the number of elongate spindle-shaped BTSM cells in 
response to insulin stimulation (closed circles), which is significantly different from serum-
deprived conditions in the absence of insulin (open circles), and which is strongly prevented in the 
presence of Y-27632 (triangles) or LY-294002 (squares). #P=0.07, *P<0.05, compared to insulin. 
 
 
We used phase contrast microscopy to quantify myocyte elongation during prolonged 





elongation were observed for up to 4 days in insulin-deficient serum-free cultures; rather, 
a relative homogenous population of BTSM cells was maintained. After 8 days, however, 
a limited number of aggregations of elongate cells similar in shape to sm-MHC and 
calponin-rich myocytes observed by immunocytochemistry were evident (Figure 5A, E). 
In contrast, in insulin-supplemented cultures, the formation of large, elongate myocytes 
was clearly evident within 2 days of serum-withdrawal, and this number increased 
markedly, nearing a plateau in number by 4 days that was only ~20% higher after 8 days 
(Figure 5B, E). These data further reveal the key role of insulin in facilitating ASM 
maturation in primary culture. 
 
As Rho-kinase and PI-3-kinase were required for contractile protein accumulation in 
BTSM cells (Figure 3), we also studied the effects of Y-27632 and LY-294002 on cell 
morphology under serum-free conditions in the presence and absence of insulin. 
Consistent with our earlier immunoblot analyses (Figure 3) Rho-kinase inhibition had 
little effect on development of elongate myocytes in insulin-deficient cultures, whereas 
inhibition of PI-3-kinase appeared to completely prevent maturation of elongate 
contractile morphology myocytes in insulin-deficient cultures. Formation of large, 
elongate contractile ASM cells during 8-days culture in insulin-supplemented serum-free 
media was however, largely dependent on both Rho-kinase and PI-3-kinase (Figure 5C, 
D & E). These findings parallel our earlier results using immunoblotting that revealed 
dependence on both Rho-kinase and PI-3-kinase for insulin-augmented accumulation of 
sm-myosin and calponin. In some experiments Trypan Blue was added to the cells to 
establish cell viability in all conditions. Although LY-294002 induced ~1% loss in cell 
viability, it was clear that at the concentrations used, these inhibitors had no significant 
effect on cell attachment nor did they promote cell death. 
 
As our data suggest that PI-3-kinase is required for myocyte maturation in the presence 
and absence of insulin, we next used fluorescence microscopy to examine whether 
activation of the downstream signaling effector, p70S6K, was selectively associated with 
BTSM cell maturation (Figure 6). After 4 days serum-withdrawal in the presence or 
absence of insulin we observed that phospho- Thr421/Ser424-p70S6K was elevated in all 
myosin-enriched myocytes. Moreover, this pattern was maintained through 8 days of 
study (not shown). These data strongly suggest that activation of PI-3-kinase, in parallel 
with the dramatic augmentation in the number of myocytes induced to a contractile 
phenotype by insulin, is associated with the accumulation of sm-MHC and calponin 











Insulin receptor identification in airway smooth muscle  
In the present study, we report significant effects of insulin in augmented ASM 
phenotype maturation. However, to date, insulin receptor expression in ASM has not 
been described, though expression of the insulin receptor and the insulin-like growth 
factor (IGF) receptors are well established in skeletal muscle [25] and vascular smooth 
muscle [26]. We performed reverse transcriptase PCR, using primers for the bovine 
insulin receptor and the bovine IGF receptors 1 and 2, to determine the profile of 
receptors expressed by primary cultured BTSM cells. In accordance with previous 
findings in rabbit ASM [27], we demonstrate the presence of mRNA for IGF receptors 1 
and 2. Moreover, we demonstrate for the first time the presence of mRNA for the insulin 




Our results demonstrate that prolonged insulin stimulation of ASM cells induces a time-
dependent increase in the expression of contractile ASM phenotypic markers in a Rho-
kinase and PI-3-kinase dependent fashion. Moreover, this is associated with the 
formation of large, elongate ASM cells that are selectively enriched in sm-MHC and 
calponin, and are highly reminiscent of previously described (hyper)contractile canine 
ASM cells [7]. To date, induction of a hypercontractile phenotype in ASM cells has been 
attributed to mechanisms associated with prolonged serum-deprivation. Our current 
studies, however, strongly indicate that insulin has a direct effect that significantly 
potentiates phenotype maturation to a far greater extent than can be attained in its 
absence in serum-free conditions. 
There has been considerable investigation on identifying signaling pathways underlying 
the development of large, elongate contractile phenotype ASM cells. An important role 
for PI-3-kinase and its downstream targets has emerged in signaling cascades that 
promote protein synthesis, differentiation and hypertrophy in ASM [13] and a variety of 
other muscle types [28-30]. Recently, it was found PI-3-kinase is required for the 
expression of sm--actin and the contraction regulatory protein MLCK in a transformed 
human bronchial smooth muscle cell line [31]. Moreover, it was demonstrated that under 
insulin-supplemented serum free conditions, PI-3-kinase mediated signaling involving 
Akt1, mTOR and p70S6K is critical for accumulation of contractile proteins such as 







Figure 6. The downstream effector of PI-3-kinase, p70S6K, is selectively activated in airway 
myocytes during maturation to a contractile phenotype. Images shown are from BTSM cells after 
4 days in serum-free culture in the absence (A-C) and presence (D-F) of insulin (1M). Myocytes 
were double labeled for both sm-MHC (red) and phospho- Thr421/Ser424-p70S6K (green). Nuclei 
(blue) are stained with Hoechst 33342. Merged images (C and F) of sm-MHC and phospho- 
Thr421/Ser424-p70S6K are also shown. Images are typical of those obtained from triplicate wells 














Figure 7. mRNA abundance of insulin target receptors in BTSM cells. Reverse transcriptase PCR 
was performed using total RNA extracted from BTSM cell cultures. (A) Photograph showing 
mRNA abundance of the bovine insulin receptor in 4 different BTSM cell cultures. Bovine liver 
was used as a positive control. (B) Photograph showing mRNA abundance of the bovine insulin-
like growth factor receptor 1 and 2 in BTSM cell cultures.  
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Another downstream target involved in PI-3-kinase/mTOR signaling is PHAS-1/4E-BP. 
Temperature-shift-induced differentiation and hypertrophy of immortalized human ASM 
cells was found to be accompanied by an augmented PI-3-kinase/mTOR-induced 
phosphorylation of PHAS-1, causing dissociation of PHAS-1 from the translation 
initiator protein eukaryotic initiation factor (eIF)-4E and subsequent increased protein 
synthesis [32]. Moreover, a direct link between insulin and PI-3-kinase signaling has 
been reported in C2C12 myoblasts; it was demonstrated that PI-3-kinase and mTOR 
were required for insulin-induced differentiation of these cells [33]. Completely in 
agreement with these findings, we now demonstrate that PI-3-kinase is required for the 
accumulation of contractile apparatus proteins and the formation of elongate, contractile 
phenotype ASM cells, both under serum-free and insulin-stimulated culture conditions. 
Notably, our studies are the first to show directly that insulin potentiates airway myocyte 
maturation in serum-free culture. 
 
An essential role for RhoA/Rho-kinase signaling in driving the transcription of genes 
encoding for contractile proteins such as sm-MHC, sm--actin, calponin and SM22 in 
smooth muscle has become evident [3,14-16]. Activation of the promoters of these genes 
is under combinatorial control by a number of transcription factors [16], but virtually all 
harbour a pair of essential CArG box elements [CC(A/T)6GG] that bind dimers of the 
MADS transcription regulator family member, SRF [14,17,18]. Localization and 
activation of SRF in the nucleus and subsequent induction of smooth muscle specific 
genes are chiefly governed by RhoA / Rho-kinase signaling in ASM [15]. The 
RhoA/Rho-kinase pathway regulates actin filament dynamics that modulate translocation 
of SRF co-activators to further support transcription of contractile smooth muscle 
specific genes [18,34]. Our present findings reveal Rho-kinase is required for the 
induction of a hypercontractile ASM phenotype in response to insulin, however the 
pathway appears to play an inconsequential role in the absence of insulin. This suggests 
that insulin stimulation may activate transcription of genes for contractile proteins. 
Although insulin-induced gene transcription has been proposed to be Rho/Rho-kinase 
dependent [35,36], clearly the specific link to this pathway is complex and requires in 
depth study, which is beyond the scope of this manuscript. Previous studies using 
transient transfection of canine ASM cells have shown that under serum-free, insulin-
supplemented conditions the activity of promoters for sm-MHC and SM22 is markedly 
reduced from that measured when cells are grown in the presence of serum [14]. 
However, to date there are no reports of studies using either luciferase reporter assays or 
assays of nuclear mRNA synthesis to assess the specific effects of insulin on 
transcription of genes that contribute directly or indirectly to the extent of (airway) 
smooth muscle specific gene expression. Though such experiments are beyond the scope 
of the present study, our current findings from studies using actinomycin D indicate 
insulin has no effect on the stability of mRNA for contractile apparatus associated 
proteins, but rather on the gene transcription of these proteins. 
 
As the use of aerosolized insulin formulations has recently been approved in the U.S.A. 





ASM function and phenotype might not only be of pharmacological interest but might 
also be of clinical relevance. We have previously demonstrated that prolonged insulin 
exposure of BTSM strips results in the induction of a functional hypercontractile 
phenotype [19]. Completely confirming those findings, we now demonstrate that insulin 
stimulation, as in BTSM cells, results in an increased contractile protein expression in 
these intact muscle strips. Several phase 2 and 3 trials for inhaled insulin formulations 
show efficacy and tolerability that is comparable to subcutaneous (s.c.) insulin use [37-
39]. Importantly, due to a low biological availability of inhaled insulin, effective dosing 
for inhaled delivery is ~10-fold higher than that used for s.c. injections to achieve 
satisfactory glycemic control [40-43]. It has not been directly determined whether large 
quantities of inhaled insulin might induce some adverse effects on ASM function, 
including ASM hypercontractility. However, it has been reported that inhalation of 
insulin might be accompanied by an increased incidence of cough, dyspnoea, sinusitis 
and pharyngitis [20]. Accordingly, very recently we have demonstrated that insulin has 
acute contractile effects on guinea pig tracheal smooth muscle preparations (DS, 
unpublished observations)[Chapter 5]. Moreover, it was reported that insulin caused a 
decrease in FEV1, which was indicated to be of small and uncertain clinical significance 
[20]. Since due to a poor absorption by asthmatics compared to healthy subjects, diabetic 
patients with asthma may need to inhale even a higher dose of insulin as compared to 
nonasthmatic diabetics [41], and since patients suffering from asthma, as well as patients 
with COPD, are hyperresponsive to inhaled contractile stimuli [44-46], it could be 
envisaged that these effects on FEV1 might be more significant in these patients. 
Moreover, effects of insulin on AHR and airway inflammation have been reported in rat 
models of diabetes [47,48]. It was found that airway constriction in response to electrical 
field stimulation was decreased in diabetic rats due to an increased function of the 
neuronal inhibitory M2-muscarinic receptor in the lungs [47]. Upon allergen challenge 
neuronal M2-receptor function was preserved and eosinophilia did not occur around 
airway nerves in these animals [48]. Conversely, treatment of these diabetic animals with 
insulin induced M2-receptor dysfunction, AHR and eosinophilia after allergen challenge. 
Further investigations are clearly warranted to identify acute and chronic effects of 
insulin on human ASM and to establish the effects of insulin inhalation on ASM 
function and phenotype under specific pathophysiological conditions (e.g. in asthma and 
COPD models).  
 
In conclusion, we demonstrate prolonged insulin stimulation induces expression of 
contractile phenotypic markers in a time-dependent fashion, completely confirming 
previous findings on ASM contractility [19]. Moreover, Rho-kinase and PI-3-kinase are 
required for the insulin-induced effects, both for contractile protein accumulation and 
formation of large, elongate contractile ASM cells. These findings might be of both 
pharmacological as pharmacotherapeutical interest and might significantly contribute to 
the ongoing discussion on the use of aerosolized insulin formulations for the treatment of 
diabetes mellitus type 1 and 2. 
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